Medically reviewed by Drugs.com. Last updated on Jan 20, 2021.
Generic name: miglustat 100mg
Dosage form: capsule
Instructions for Administration
Therapy should be directed by physicians who are knowledgeable in the management of Gaucher disease.
The recommended dose for the treatment of adult patients with type 1 Gaucher disease is one 100 mg capsule administered orally three times a day at regular intervals. If a dose is missed, the next ZAVESCA capsule should be taken at the next scheduled time.
It may be necessary to reduce the dose to one 100 mg capsule once or twice a day in some patients due to adverse reactions, such as tremor or diarrhea.
Patients with Renal Insufficiency
In patients with mild renal impairment (adjusted creatinine clearance 50–70 mL/min/1.73 m2), initiate ZAVESCA treatment at a dose of 100 mg twice per day. In patients with moderate renal impairment (adjusted creatinine clearance of 30–50 mL/min/1.73 m2), initiate ZAVESCA treatment at a dose of one 100 mg capsule per day. ZAVESCA is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min/1.73 m2) [see Use in Specific Populations (8.6)].
More about Zavesca (miglustat)
- Side Effects
- During Pregnancy or Breastfeeding
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Generic Availability
- Drug class: miscellaneous metabolic agents
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.